New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
08:43 EDTVRTXVertex shares should be owned ahead of data, says JMP Securities
JMP Securities expects Phase 3 data for Kalydeco in combination with corrector lumacaftor, expected to be announced mid-year, to be positive. It recommends that ivnestors own the stock ahead of the data. The firm notes that Vertex received a label expansion for Kalydeco fro mthe FDA, and it reiterates a $115 price target and Outperform rating on the stock.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
13:42 EDTVRTXVertex peak CF sales have bullish read from Royalty Pharma bet, TheStreet says
Subscribe for More Information
10:42 EDTVRTXUBS hosts a conference call with Vertex Pharmaceuticals
Subscribe for More Information
07:52 EDTVRTXInforma Business Information to hold a conference
Subscribe for More Information
07:27 EDTVRTXRoyalty Pharma acquires royalties on Vertex Pharmaceuticals CF treatments
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use